Description

Lanifibranor is a potent, orally active pan-peroxisome proliferator-activated receptor (PPAR) agonist, specifically targeting the alpha, delta, and gamma subtypes. This compound is a key investigational pharmaceutical intermediate with significant therapeutic potential for the treatment of metabolic and fibrotic diseases. It is primarily utilized by pharmaceutical R&D organizations and contract manufacturing organizations (CMOs) engaged in the development of novel treatments for non-alcoholic steatohepatitis (NASH) and other related conditions.

Application

• Pharmaceutical Intermediate: Critical raw material for the synthesis of advanced investigational drug substances targeting metabolic disorders.
• Non-Alcoholic Steatohepatitis (NASH) Research: Serves as the active pharmaceutical ingredient (API) in clinical and preclinical studies for novel NASH therapeutics.
• Metabolic Disease R&D: Used in research programs focused on diabetes, insulin resistance, and dyslipidemia due to its pan-PPAR agonist activity.
• Liver Fibrosis Studies: Applied in investigative studies for anti-fibrotic agents, given its mechanism of action.
• Reference Standard: Employed as an analytical standard in quality control laboratories for method development and validation.
• Process Chemistry Development: Used for scaling up and optimizing synthetic routes in process R&D within pharmaceutical manufacturing.

Basic Information

Product Name	Lanifibranor
CAS No.	927961-18-0
Molecular Formula	C₂₄H₂₀F₃NO₄
Molecular Weight	443.42 g/mol
Synonyms	IVA337; 2-[2,6-Dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methylpropanoic Acid; 4-[(1E)-3-[4-(Methylsulfanyl)phenyl]-3-oxoprop-1-en-1-yl]-2,6-dimethylphenoxy-2,2-dimethylpropanoic Acid; Lanifibranor (USAN); 2-Methyl-2-[4-[(1E)-3-[4-(methylsulfanyl)phenyl]-3-oxoprop-1-en-1-yl]-2,6-dimethylphenoxy]propanoic Acid
EINECS	Contact for details

Quality Control

Our Lanifibranor is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency, meeting the stringent requirements for pharmaceutical intermediates. A comprehensive Certificate of Analysis (COA) is provided with each shipment, detailing results for assay, related substances, residual solvents, and other critical parameters. We support regulatory filings with full traceability and documentation.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under inert atmosphere or in a desiccated environment after opening to maintain stability and prevent degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.